Deferitazole, formerly known as FBS-0701 and SPD-602, is a new orally bioavailable Antimalarial iron chelator for the treatment of transfusional iron overload. Deferitazole exhibits a high affinity and selectivity for iron(III) as demonstrated by the log β2 = 33.39 ± 0.03 and the pFe(3+) value of 22.3. Deferitazole scavenges iron from labile sources such as citrate and albumin with efficiencies comparable with those of other therapeutic iron chelators, including deferasirox, deferiprone and desferrioxamine. FBS0701 blocks transmission by Plasmodium falciparum gametocyte. References: Hider RC, Kong X, Abbate V, Harland R, Conlon K, Luker T. Deferitazole, a new orally active iron chelator. Dalton Trans. 2015 Mar 21;44(11):5197-204. doi: 10.1039/c5dt00063g. PubMed PMID: 25687725.

纯度：≥98%

CAS：945635-15-4